ADMA Biologics Q2 revenue $107.2M (+78% YoY); raises FY2024 revenue guidance to >$400M

ADMA BIOLOGICS, INC.

2024-Q2 EPS reported $0.21 revenue$189,066,000

Q2 2024 total revenue $107.2M, up 78% YoY; GAAP net income $32.1M vs loss of $6.4M a year ago.
Adjusted EBITDA $44.5M, up ~592% YoY; gross margin improved to 53.6% from 27.8%.
FY2024 revenue guidance raised to >$400M (from >$355M); FY2025 revenue >$445M (from >$410M).
FY2024 GAAP net income guidance raised to >$105M; adjusted EBITDA guidance >$150M.
Commercial-scale yield enhancement of ~20% from same starting plasma; potential benefit as early as Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.